Beyond market trends, investors looking for superior returns explore the world of stock picking. The right selections can be a powerful driver for wealth accumulation.
In the latest session, Novo Nordisk ADR (NYSE: NVO) closed at $61.85 up 6.27% from its previous closing price of $58.2. In other words, the price has increased by $6.27 from its previous closing price. On the day, 24.52 million shares were traded. NVO stock price reached its highest trading level at $62.25 during the session, while it also had its lowest trading level at $60.84.
Ratios:
For a deeper understanding of Novo Nordisk ADR’s stock, let’s take a closer look at its various ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 69.89 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 21.94. For the most recent quarter (mrq), Quick Ratio is recorded 0.56 and its Current Ratio is at 0.78. In the meantime, Its Debt-to-Equity ratio is 0.59 whereas as Long-Term Debt/Eq ratio is at 0.52.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on May 30 ’25 when Novo Nordisk A/S bought 921,897 shares for $2.14 per share.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, NVO now has a Market Capitalization of 276276674560 and an Enterprise Value of 355160162304. As of this moment, Novo’s Price-to-Earnings (P/E) ratio for their current fiscal year is 17.04, and their Forward P/E ratio for the next fiscal year is 14.90. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 1.35. For. The Stock, the TTM Price-to-Sale (P/S) ratio is 4.58 while its Price-to-Book (P/B) ratio in mrq is 10.39. Its current Enterprise Value per Revenue stands at 1.139 whereas that against EBITDA is 2.23.
Stock Price History:
The Beta on a monthly basis for NVO is 0.69, which has changed by -0.51494 over the last 52 weeks, in comparison to a change of 0.16298151 over the same period for the S&P500. Over the past 52 weeks, NVO has reached a high of $135.20, while it has fallen to a 52-week low of $45.05. The 50-Day Moving Average of. The Stock is 7.91%, while the 200-Day Moving Average is calculated to be -15.79%.
Shares Statistics:
For the past three months, NVO has traded an average of 16.28M shares per day and 15993630 over the past ten days. A total of 3.37B shares are outstanding, with a floating share count of 3.37B. Insiders hold about 0.00% of the company’s shares, while institutions hold 9.35% stake in the company. Shares short for NVO as of 1756425600 were 25777443 with a Short Ratio of 1.58, compared to 1753920000 on 20756474. Therefore, it implies a Short% of Shares Outstanding of 25777443 and a Short% of Float of 0.77.
Dividends & Splits
According to the company, the forward annual dividend rate for NVO is 1.73, from 11.65 in the trailing year. Against a Trailing Annual Dividend Yield of 0.20017181. The Stock’s 5-year Average Dividend Yield is 1.51. The current Payout Ratio is 35.93% for NVO, which recently paid a dividend on 2025-03-31 with an ex-dividend date of 2025-08-18. Stock splits for the company last occurred on 2023-09-20 when the company split stock in a 2:1 ratio.
Earnings Estimates
Investors are eagerly awaiting the insights provided by 3.0 analysts currently analyzing and rating. The Stock of Novo Nordisk ADR (NVO).The consensus estimate for the next quarter is $6.2, with high estimates of $6.67 and low estimates of $5.69.
Analysts are recommending an EPS of between $25.73 and $22.28 for the fiscal current year, implying an average EPS of $24.28. EPS for the following year is $25.18, with 2.0 analysts recommending between $25.37 and $24.99.
Revenue Estimates
A total of 7 analysts believe the company’s revenue will be $76.43B this quarter.It ranges from a high estimate of $79.65B to a low estimate of $74.03B. As of the current estimate, Novo Nordisk ADR’s year-ago sales were $71.31BFor the next quarter, 7 analysts are estimating revenue of $81.79B. There is a high estimate of $83.17B for the next quarter, whereas the lowest estimate is $79.68B.
A total of 19 analysts have provided revenue estimates for NVO’s current fiscal year. The highest revenue estimate was $322B, while the lowest revenue estimate was $307.19B, resulting in an average revenue estimate of $314.74B. In the same quarter a year ago, actual revenue was $290.4BBased on 20 analysts’ estimates, the company’s revenue will be $338.83B in the next fiscal year. The high estimate is $392.37B and the low estimate is $317.87B.
